New York Bets on Contingency Management as Stimulant Use Disorder Lacks Approved Drugs
New York is preparing to launch an 18-month pilot that could become a template for treating stimulant use disorder in outpatient care, even as state leaders work to preserve gains in opioid use disorder treatment. The plan centers on contingency management, a behavioral approach built on small, repeated incentives for stimulant-negative toxicology results and steady clinic attendance. In a field where no FDA-approved medication exists for stimulant use disorder, the program is being positioned as a practical, evidence-based option rather than an experimental add-on.
The pilot will start with eight outpatient non-OTP sites next month. For the first 12 weeks, patients with primary stimulant use disorder will come to clinic twice weekly, several days apart, and undergo urine toxicology testing on site. A stimulant-negative result will trigger a gift card worth about $15. After that initial phase, visits will drop to once weekly for another 12 weeks, and the incentive can climb over time to as much as $750, consistent with current SAMHSA allowances. A missed appointment or return to stimulant use resets the reward to zero.
That structure matters because contingency management works on immediate reinforcement, not distant promises. Stimulant use disorders are notoriously difficult to treat in routine practice, especially when patients face unstable housing, transportation barriers, psychiatric comorbidity, or inconsistent contact with care. Small, predictable incentives can change behavior in ways counseling alone often cannot, particularly when the desired outcome is biologically simple to verify at the point of care: a negative urine test.
Chinazo Cunningham, commissioner of New York’s Office of Addiction Services and Supports, framed the pilot as a response to a stubborn clinical gap. Stimulant use disorder now affects slightly more Americans than opioid use disorder, yet providers still lack a medication-first toolkit. The program is also designed to overcome a long-standing implementation problem. Contingency management has been studied for decades and has repeatedly shown benefit, but scaling it in real-world clinics has remained difficult, even in highly funded research settings.
Cunningham’s own NIH-funded, seven-year study reached the same wall. Even with a large annual budget, she described the logistics as hard to pull off. In routine care, the barrier is not whether the intervention works in principle; it is whether clinics can sustain the urine testing, staff workflow, incentive tracking, and rapid reinforcement needed to make it function as intended. New York’s pilot is meant to answer that operational question in ordinary outpatient settings, where success or failure will likely depend on whether the process is simple enough for programs to absorb without collapsing under administrative strain.
Incentives, Toxicology, and the Real-World Limits of Behavioral Treatment
The state’s design reflects how closely the biology of stimulant use disorder follows behavior. Drug use patterns are reinforced by immediate neurochemical reward, and contingency management attempts to counterbalance that loop with an equally immediate external reward. In practice, the intervention only works if the patient experiences a clear connection between abstinence and incentive. Delays dilute the effect; vague requirements make it less persuasive; uneven clinic follow-up weakens the entire model.
New York will also rely on an 1115 waiver to seek reimbursement for the care, though the current waiver expires in March 2027 and renewal remains under review. SAMHSA previously capped financial incentives at $75, a ceiling Cunningham said was too low to drive meaningful behavior change. The newer allowance to reach $750 gives clinics more room to build escalation into the program, an important feature because larger and steadily increasing rewards are often central to the method’s durability.
The pilot is being launched at a moment when the state has already made substantial gains in opioid care. Flexible dosing policies for medications for opioid use disorder, first adopted during COVID-19 and made permanent in 2024, have expanded access for patients who cannot reliably travel to an OTP every day. New York now has 140 outpatient methadone programs, and state leaders say access to MOUD has widened in prisons and jails as well. Those gains do not solve stimulant use disorder, but they create a policy backdrop in which addiction treatment is being treated as a systems problem rather than a single-drug problem.
At Strong Recovery in Rochester, clinical leaders have already adapted to the changing MOUD environment by separating medication access from therapy requirements and adding an engagement specialist to track patients who have disengaged from counseling. The same kind of operational flexibility will likely be needed in the stimulant pilot. Programs will have to keep patients connected, monitor safety, and decide quickly what happens when someone misses visits or relapses.
Medicaid Work Rules Threaten Coverage Stability in 2027
The stimulant pilot is arriving just as New York prepares for broader Medicaid disruption under H.R. 1 changes. State officials estimate that up to a million Medicaid enrollees could be subject to new work requirements, and those changes could affect the continuity of addiction treatment if coverage lapses or eligibility is delayed. Starting Jan. 1, 2027, new applicants will need to show compliance for the month before application, while existing members will face renewal dates in March.
New York plans to use attestation during the first year, meaning members will answer a short questionnaire while the state gathers supporting documentation. After 2028, that approach will no longer be allowed. Officials are also building a risk-tiered provider revalidation process, shifting from a paper-based system that proved unreliable to a digital workflow. For addiction care, the concern is straightforward: when coverage rules become harder to navigate, patients already vulnerable to relapse can disappear from treatment just as programs are trying to expand access.
The state is also trying to blunt administrative fallout with a customer service line dedicated to H.R. 1 questions, notice campaigns, social media and television outreach, and more assistors to help members complete applications. Those are bureaucratic responses to a clinical problem. Addiction care depends on continuity, and continuity depends on insurance, documentation, and the ability of a patient in crisis to re-enter treatment without being derailed by paperwork.
For now, the most concrete clinical experiment in the state is the stimulant use disorder pilot. If it performs well, New York plans to scale it statewide. If it falters, the failure will likely say less about the pharmacology of contingency management than about how hard it remains to build a behavioral treatment that is both evidence-based and operationally durable in everyday outpatient practice.